Pfizer (PFE) has entered into three settlement agreements for VYNDAMAX. As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031.
- Deals with: Dexcel Pharma, Hikma Pharmaceuticals (HIK LN) and Cipla (CIPLA)
Context
Pfizer's settlement agreements for VYNDAMAX, involving Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, signify a strategic move to stabilize future revenues through 2031. This consistency in revenue expectations may bolster investor confidence and influence analysts' outlooks on Pfizer's performance in the pharmaceutical space, particularly in the EU and US markets.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED KINGDOM#EUROPE#PFIZER INC#PFE.US#HIKMA PHARMACEUTICALS PLC#HIK.LN#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#FTSE 100 INDEX#PFE#HIK#US EQUITIES